Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

Diabetologia

Volumn 49, Issue 9, 2006, Pages 2049-2057

  Matikainen, N ^a   Manttari S ^a   Schweizer, A ^b   Ulvestad, A ^b   Mills, D ^b   Dunning, B E ^c   Foley, J E ^b   Taskinen, M R ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PharmaWrite LLC   (United States)

Author keywords

Apo B 48; Dipeptidyl peptidase IV inhibitors; Postprandial lipids; Triglyceride rich lipoproteins; Type 2 diabetes; Vildagliptin

Indexed keywords

APOLIPOPROTEIN B48; CHOLESTEROL; CHYLOMICRON; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL; VILDAGLIPTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HEMATURIA; HUMAN; HYPOGLYCEMIA; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL;

ADAMANTANE; ANTIGENS, CD26; APOLIPOPROTEIN B-48; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INTESTINES; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; NITRILES; POSTPRANDIAL PERIOD; PYRROLIDINES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 33746690405     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0340-2     Document Type: Article

References (28)

1. Mari A, Sallas WM, He YL et al (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894
2. Ahrén B, Landin-Olsson M, Jansson P-A et al (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084
3. Qin X, Shen H, Liu M et al (2005) GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 288:G943-G949
4. Wasada T, McCorkle K, Harris V et al (1981) Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Invest 68:1106-1107
5. Ebert R, Nauck M, Creutzfeldt W (1991) Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats. Horm Metab Res 23:517-521
6. Taskinen M-R (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733-749
7. De Man FHAF, Cabezas MC, Van Barlingen HHJJ, Erkelens DW, de Bruin TWA (1996) Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 26:89-108
8. Mero N, Malmstrom R, Steiner G, Taskinen MR, Syvanne M (2000) Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 150:167-177
9. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A (2004) Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880
10. Mero N, Syvanne M, Eliasson B, Smith U, Taskinen MR (1997) Postprandial elevation of ApoB-48-containing triglyceride-rich particles and retinyl esters in normolipemic males who smoke. Arterioscler Thromb Vasc Biol 17:2096-2102
11. Karpe F, Hamsten A (1994) Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res 35:1311-1317
12. Havekes LM, de KP, Beisiegel U et al (1987) A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 28:455-463
13. Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H (1976) Glucose tolerance and insulin release, a mathematical approach. I. Assay of the beta-cell response after oral glucose loading. Diabetes 25:241-244
14. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470
15. Cohn JS, McNamara JR, Krasinski SD, Russell RM, Schaefer EJ (1989) Role of triglyceride-rich lipoproteins from the liver and intestine in the etiology of postprandial peaks in plasma triglyceride concentration. Metabolism 38:484-490
16. Adiels M, Taskinen MR, Packard C et al (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49:755-765
17. Maggs DG, Buchanan TA, Burant CF et al (1998) Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomised, double-blind, placebo-controlled trial. Ann Intern Med 128:176-185
18. Tan GD, Fielding BA, Currie JM et al (2005) The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:83-95
19. van Wijk JP, de Koning EJ, Castro CM, Rabelink TJ (2005) Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 28:844-849
20. Majali KA, Cooper MB, Staels B et al (2006) The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 49:527-537
21. Jeppesen J, Zhou MY, Chen YD, Reaven GM (1994) Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 17:1093-1099
22. Abbasi F, Chu JW, McLaughlin T et al (2004) Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 53:159-164
23. Jeppesen J, Zhou MY, Chen YD, Reaven GM (1994) Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM. Diabetologia 37:781-787
24. Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR (2002) Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 18:484-490
25. Nauck MA, Niedereichholz U, Ettler R et al (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulin-otropic effects in healthy humans. Am J Physiol Endocrinol Metab 273:E981-E988
26. Schirra J, Goke B (2005) The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul Pept 128:109-115
27. Meier JJ, Gethmann A, Gotze O et al (2006) Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49:452-458
28. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M (2005) Type 2 diabetes as a 'coronary heart disease equivalent': an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28:2901-2907